In the first quarter (Q1) of 2025, Stryker Corporation (SYK) reported strong organic growth and strategic shifts. The company surpasses Q1 earnings estimates. Revenue exceeded expectations at $5.9 billion, although the EPS fell short at $1.69. Despite these impressive results, CEO compensation increases might be put on hold.
Stryker's balance sheet is in a robust state, perhaps contributing to the rise in institutional ownership, currently at 79%. Earnings highlighted growth and soon-to-announce financial results for Q1 of fiscal year 2025 are expected. However, the company lowers adjusted EPS view due to $200 million tariff impact.
A notable strategic shift is in the form of acquisitions. Stryker completes the acquisition of Inari Medical Inc, marking its entry into the high-growth peripheral vascular segment. Jim Cramer speaks favorably of Stryker, seeing big gains despite tariff worries, and suggesting investors buy and 'forget about it.'
Despite the disappointing EPS view, Stryker ranks among billionaire Ken Fisher's healthcare stock picks with massive upside potential. The corporation recently introduced AI-driven innovations and continues to lead in robotic-assisted surgery.
Stryker Corporation SYK News Analytics from Tue, 01 Oct 2024 07:00:00 GMT to Sat, 03 May 2025 04:17:16 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor -6
